Eye (London, England)
TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.
Carl Regillo, Peter K Kaiser, Peter J Kertes, Mark Gillies, Tina Maio-Twofoot, David Lawrence, Frank G Holz
Published: 202510.1038/s41433-025-04161-x
Abstract
OBJECTIVE: To compare the efficacy and safety of brolucizumab 6 mg and aflibercept 2 mg in patients with neovascular age-related macular degeneration (nAMD) using an identical 4-week adjustment Treat-and-Extend regimen. METHODS: Patients received bro…
Preview only. Read the full abstract at the source